ADVERTISEMENT
In Vitro Characterization of Variable Porosity Wound Dressing With Anti-Scar Properties
| In Vitro Characterization of Variable Porosity Wound Dressing With Anti-Scar Properties | |
| ,a ,b ,c ,a ,d a,d | |
aDepartment of Environmental Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY; bPermeaDerm, Inc, Carlsbad, Calif; cDepartment of Plastic Surgery, University of Virginia, Charlottesville; and dDepartment of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, NY |
|
Correspondence: collynn_woeller@urmc.rochester.edu |
|
| Keywords: salinomycin, excessive scarring, myofibroblast, mesenchymal stem cell, antimicrobial |
| Introduction: New options are needed to improve wound healing while preventing excessive scar formation. Temporary primary dressings are important options in topical wound management that allow the natural healing process. Methods: We evaluated a novel primary dressing consisting of a biosynthetic, variable porosity, matrix-containing gelatin and Aloe Vera extract and a derivative dressing coated with the anti-scarring agent salinomycin for their ability to promote cell growth, reduce myofibroblast formation, and regulate cytokine production. In addition, salinomycin-coated primary dressings were tested for antimicrobial activity. Results: Both primary wound dressings permitted cell growth and attenuated TGFβ-induced scar-forming myofibroblast formation. The primary wound dressings also reduced IL-6 production by 50%, IL-8 by 20%, MCP-1 by 75%, and GRO by 60% in human mesenchymal stem cells treated with TGFβ. Salinomycin coating of the dressing showed antimicrobial activity by preventing Staphylococcus aureus growth. Conclusions: Both primary wound dressings support the growth of human fibroblasts and stem cells, as well as reduce inflammatory cytokine production, demonstrating their potential to serve as temporary wound dressings. |
Excessive scar formation can be a devastating consequence of wound healing after injury from chemical or physical burns of the skin and other organs.1,2 Debilitating scarring results in pain, loss of tissue function, and, in severe cases, even death.3 New treatments to prevent scarring are needed.4 One option in topical wound healing is the use of temporary dressings that aim to allow the natural healing process with minimal scar formation.5 In addition, slow-healing or chronic wounds require excision and/or debridement of necrotic tissue and often containment with a suitable dressing or skin substitute.6 The main goal of this technique is protection of viable tissue and minimization of infection complications. This can be accomplished with an adherent “Smart Dressing” or “Bioengineered Alternative Tissue” that keeps fluid accumulation beneath the primary dressing at a minimum and reduces dressing changes and pain (morbidity).
Surface wound healing of skin is a process in which resident fibroblasts and other progenitor stem cells grow and repair damaged tissue areas. Often in cases of severe burns, chronic inflammation, or other persistent injury, healing can proceed out of control with the accumulation of contractile myofibroblasts, key effector cells that mediate scarring.7 Myofibroblasts and their excessive production of extracellular matrix material result in tissue remodeling, scarring, morbidity, and eventually loss of tissue function.7 Myofibroblasts also secrete a variety of cytokines and chemokines including transforming growth factor beta (TGFβ), interleukin (IL)-6, GRO (also called CXCL1), monocyte chemoattractant protein-1 (MCP-1), and IL-8 that lead to further myofibroblast activation, tissue inflammation, and damage.8
Here, we evaluated the efficacy of a novel acellular bilaminate primary dressing consisting of a clinician-controlled, variable porosity, bilaminate matrix made of nylon mesh and silicone that contains gelatin and Aloe Vera extract (called Immuno-10)9 for chronic wounds (dressing C). We also evaluated derivatives of the primary dressing coated with the anti-scarring agent salinomycin (dressing A).6 We discovered that salinomycin, a natural antibiotic produced by Streptomyces albus and used as a coccidiostatic agent in animal feed, is a powerful anti-scarring agent.4,6,10 Our published studies show that salinomycin potently blocks TGFβ-dependent myofibroblast formation and function.4,10 Thus, a combination approach of a temporary primary skin dressing and an anti-scarring agent represents a novel method to combat scarring while promoting wound healing.
METHODS
Primary wound dressing production
Acellular bilaminate primary dressings were produced as previously described.6,9 Briefly, the dressings were made from a biological coating of 3-dimensional (3D) matrix containing gelatin and Aloe Vera extract (Immuno-10)9 added to a silicone membrane with a nylon mesh (referred to as dressing C). The anti-scarring dressing (referred as dressing A for anti-scar) was made in the same manner, except with salinomycin added in both the silicone and biological component. Dressing sterilization was performed by exposing each dressing to 25 kGy of electron beam radiation.
Cell culture and staining
Human fibroblasts and primary human adipose-derived mesenchymal stem cells (Ad-MSCs) were acquired and cultured as previously described.11 Cells were grown in 24-well culture dishes with either no matrix or dressing C or A, treated with vehicle (PBS) or TGFβ (5 ng/mL) for 72 hours, and then fixed with 2% paraformaldehyde for 10 minutes. Cells were rinsed 3 times in PBS and stained with DAPI (a fluorescent nucleic acid–binding dye) and AlexaFluor 594–conjugated phalloidin (an actin filament–binding peptide; Invitrogen, Carlsbad, Calif). Cells were visualized on an EVOS-FL Fluorescent Imaging System (Invitrogen), and the same instrument settings were used to acquire each image.
Analysis of cytokine production
A multiplex bead sandwich ELISA panel (Luminex assay; Luminex Corp, Austin, Tex) that included 4 cytokines and chemokines associated with inflammation, wound healing, and scar formation, GRO, IL-6, IL-8, and MCP-1 (MilliporeSigma, Burlington, Mass), was used. Cell culture media (50 μL) from triplicate wells were assayed to measure production of these mediators using a Luminex FlexMAP 3D instrument following the manufacturer's instructions.
Cell viability assay
Ad-MSCs were plated in black 24-well plates (Griener; Sigma-Aldrich, St Louis, Mo) containing either no matrix or dressing C or A with 800 μL of culture medium. Vehicle (PBS), TGFβ (5 ng/mL), or IL-1β (100 pg/mL) was added, cells were incubated for 24 hours, and then Alamar blue reagent (Invitrogen) was added to each well as directed by the manufacturer's instructions. Fluorescence of the oxidized Alamar blue reagent was measured at times indicated using a Varioskan Flash instrument (ThermoFisher, Waltham, Mass) and normalized to vehicle-treated cells.
Antimicrobial assay
The ability of salinomycin to inhibit Staphylococcus aureus (S aureus strain UAMS-1)12 growth was tested by the Kirby-Bauer agar diffusion method.13 Salinomycin (39 μM to 2.5 mM) was spotted in 4-μL drops onto 6-mm diameter filter discs (120 ng to 7.5 μg of salinomycin per disc). A commercially available disc containing 30 μg of the antibiotic vancomycin (BD-BBL, Sparks, Md) was used as a positive control. Discs were added to agar plates containing methicillin-sensitive S aureus and incubated at 37°C overnight. Zone of inhibition areas were documented by imaging of the agar plates. Next, 12-mm sections of dressing C were soaked for 24 hours in a mixture of DMSO/ethanol (50:50 mix) with or without various concentrations of salinomycin (30 μg/mL to 7.5 mg/mL) and then allowed to dry for another 24 hours. Matrix was then placed on an agar plate containing S aureus and incubated at 37°C overnight. Zone of inhibition and kill zone areas were documented as previously.
Statistical analysis
GraphPad Prism software (La Jolla, Calif), Student's t test, and 1-way analysis of variance were used for statistical analysis, and values of P < .05, P < .01, and P < .001 were considered significant. Data are expressed as mean ± standard error of the mean.
RESULTS
Novel primary wound dressings allow growth of fibroblasts and mesenchymal stem cells
Human dermal fibroblasts were plated in standard culture dishes with or without temporary wound dressing in the presence of or absence of TGFβ (5 ng/mL) for 5 days to allow cell growth and myofibroblast formation. Cells were then fixed and incubated with phalloidin (AlexaFluor 594 conjugate) that binds and stains stress fibers of filamentous actin, a prominent feature of scar-forming myofibroblasts. Cells were also coincubated with DAPI, a nucleic acid–binding dye that stains cell nuclei (Fig 1).14 Fibroblasts cultured with TGFβ for 5 days show prominent filamentous actin stress fibers that are contractile myofibroblast markers (Fig 1a vs Fig 1b). Figures 1c and 1d show representative images of human dermal fibroblasts treated with TGFβ for 5 days in the presence of the acellular bilaminate primary dressings. Note that the nylon mesh component of the dressing fluoresces blue. Dermal fibroblasts grow well with dressing C and maintain a high level of filamentous actin, whereas there is a reduction of stress fibers in cells grown with dressing A.
 |
| Figure 1. The novel primary wound dressings reduce myofibroblast formation in human dermal fibroblasts. Human dermal fibroblasts were cultured with or without temporary wound dressings in the presence of TGFβ (5 ng/mL) for 5 days. Cells were then fixed and stained with AlexaFluor 594–conjugated phalloidin (yellow, binds and stains filamentous actin) and DAPI (blue, binds nucleic acids and stains cell nuclei) for fluorescence imaging. (a) Vehicle-treated cells; (b) TGFβ-treated cells; (c) TGFβ with dressing C; and (d) TGFβ with dressing A. Original magnification ×200. |
Mesenchymal stem cells and other progenitor cells can be activated and/or recruited to a wound site. Therefore, we also tested whether Ad-MSCs can grow in the presence of these temporary wound dressings (Fig 2).6,8 Ad-MSCs were plated, treated, and stained in a similar manner as described previously. TGFβ induced the myofibroblast phenotype in Ad-MSCs (Fig 2b). Interestingly, Ad-MSCs grew effectively in the presence of either primary dressing (Figs 2c and 2d).
 |
| Figure 2. The novel primary wound dressings reduce myofibroblast formation in human mesenchymal stem cells. Human adipose-derived mesenchymal stem cells were cultured with or without temporary wound dressings in the presence of TGFβ (5 ng/mL) for 5 days. Cells were then fixed and stained with AlexaFluor 594–conjugated phalloidin (yellow, binds and stains filamentous actin) and DAPI (blue, binds nucleic acids and stains cell nuclei) for fluorescence imaging. (a) Vehicle-treated cells; (b) TGFβ-treated cells; (c) TGFβ with dressing C; and (d) TGFβ with dressing A. Original magnification ×200. |
Novel primary wound dressings reduce inflammatory cytokine production
Mesenchymal stem cell and myofibroblasts at the wound site are a source of inflammatory mediators such as IL-6, IL-8, MCP-1, and GRO.15,16 To assess whether dressings C and/or A alter inflammatory mediator production, Ad-MSCs were cultured in the presence or absence of the temporary wound dressings for 4 days with or without TGFβ. Conditioned culture medium was collected and analyzed for IL-6, MCP-1, IL-8, and GRO. Without a wound dressing, Ad-MSCs produced all 4 mediators (IL-6: 150 pg/mL; MCP-1: 130 pg/mL; IL-8: 460 pg/mL; and GRO: 65 pg/mL; Figs 3a-3d). TGFβ increased Ad-MSC production, especially MCP-1 (215 pg/mL) and GRO (100 pg/mL). Interestingly, dressings C and A significantly reduce inflammatory cytokine levels. Dressing C reduced IL-6 production to 90 pg/mL, MCP-1 to 55 pg/mL, IL-8 to 350 pg/mL, and GRO to 25 pg/mL in Ad-MSCs treated with TGFβ. Dressing A showed a more robust reduction in IL-6 (down to 60 pg/mL) and MCP-1 (down to 25 pg/mL). One possible explanation for this result may be that the temporary dressings absorb cytokines to prevent their detection. To test this, conditioned medium was collected and incubated with or without dressing C matrix for 24 hours. After incubation, medium was analyzed by Luminex and no significant differences were detected, showing that dressings C and A reduce inflammatory mediator production directly.
 |
| Figure 3. Human mesenchymal stem cells express lower levels of proinflammatory cytokines when cultured with the novel primary wound dressings. Human mesenchymal stem cells were cultured in the presence or absence of dressing C or A for 4 days in the presence or absence of TGFβ before supernatants were collected and analyzed by Luminex for production of the inflammatory cytokines, IL-6 (a), MCP-1 (b), IL-8 (c), and GRO, also called CXCL1 (d). The assay was performed in triplicate, and data are presented as mean ± SEM (*P < .05, **P < .01, ***P < .001 compared with no membrane). |
One mechanism where these temporary wound dressings could decrease cytokine production is by decreasing cell viability. Thus, we determined whether or not cell viability or growth was affected by the presence of these wound dressings. Importantly, the fluorescent images shown in Figures 1 and 2 reveal that cells grown with or without wound dressings appear morphologically as expected, without noticeable apoptotic or necrotic cells. To further quantitatively measure that these dressings do not reduce cell viability, Ad-MSCs were treated with vehicle (DMSO), IL-1β (100 pg/mL), or TGFβ (5 ng/mL) in the presence of the redox-sensitive fluorescent dye, Alamar blue.4,17 The fluorescence intensity (relative fluorescence units or RFUs) increased for all samples over time (Fig 4). At earlier time points (16-48 hours), cells grown in the presence of either dressing showed lower RFUs, suggesting reduced metabolic activity; however, after 72 hours, all treatments had similar RFUs, demonstrating robust cell viability of cells grown in the presence of the temporary wound dressings.
 |
| Figure 4. Human mesenchymal stem cells grow and are viable in the presence of the temporary wound dressings. Human adipose-derived mesenchymal stem cells were treated with vehicle (DMSO), IL-1β (100 pg/mL), or TGFβ (5 ng/mL) with Alamar blue reagent as described in the “Methods” section, and fluorescence was measured to quantify viability and cell growth. The assay was performed in triplicate, and data are presented as mean ± SEM. RFU indicates relative fluorescence unit. |
Salinomycin-coated dressings have antimicrobial activity
The ability of salinomycin to inhibit S aureus growth was evaluated by a modification of the Kirby-Bauer agar diffusion method.13 Salinomycin (120 ng to 7.5 μg) was spotted onto 6-mm diameter filter discs. A negative control of DMSO (vehicle) was used, and a disc containing vancomycin (30 μg) was used as a positive control. Discs were added to agar plates containing methicillin-sensitive S aureus strain UAMS-112 and incubated at 37°C overnight. Bacterial growth was observed around the control disc, whereas the vancomycin disc showed a stark zone of inhibition. Salinomycin showed defined zones of complete and partial inhibition (Fig 5a). Next, 12-mm diameter dressing C sections were soaked in salinomycin (30 μg/mL to 7.5 mg/mL) and used in an agar diffusion assay. Dressing C without salinomycin showed no inhibition, whereas a moderate zone of inhibition was observed with dressing C coated with 230 μg/mL of salinomycin (Fig 5b). Increasing concentrations of salinomycin showed a larger zone of inhibition (Fig 5c). These results show that dressings coated with salinomycin possess antimicrobial activity against S aureus, a prominent cause of wound infections.
 |
| Figure 5. Salinomycin-coated dressings have antimicrobial activity against S aureus. (a) Salinomycin (120 ng to 7.5 μg) was spotted onto 6-mm diameter filter discs. Vancomycin (30 μg) was used as a positive control. Discs were added to agar plates containing S aureus strain UAMS-1 and incubated at 37°C overnight. Zones of inhibition are labeled. (b, c) 12-mm diameter sections of dressing C were soaked with various concentrations of salinomycin (30 μg/mL to 7.5 mg/mL). Dressing C was then placed on an agar plates containing S aureus and incubated as previously. Dressing C without salinomycin showed no zone of inhibition, whereas a zone of inhibition was observed with dressing C coated with 230 μg/mL of salinomycin. |
DISCUSSION
Our studies using human fibroblasts and mesenchymal stem cells offer critical insights into how dressings C and A support the growth of cells while limiting excessive scar cell formation and inflammatory mediator production. Human cells grow well in the presence of temporary wound dressings, and, excitingly, dressing A dramatically reduced, but did not eliminate, filamentous actin stress fibers. A scarred tissue loses mobility and function as a consequence of hypercellularity and tissue remodeling, particularly within the myofibroblast population, which secretes high levels of inflammatory signaling molecules that further activate the tissue. Cells grown in the presence of dressings C and A displayed reduced production of inflammatory signaling molecules, highlighting another important phenotype modification that may limit excessive scar formation.
Another important observation is that dressing A retains the anti-scarring and antimicrobial ability of salinomycin.4 Our novel findings demonstrate that salinomycin can function as an anti-scarring agent when it is directly coated onto the dressing C matrix. The capacity of these acellular bilaminate dressings to be coated in both the silicone and biological components with an anti-scar agent reveals the potential for further optimization of primary wound dressing formulations.
While this work shows the efficacy of these primary wound dressings to serve as anti-scarring and antimicrobial agents in vitro, there are some limitations within the study. Wound healing occurs in a complex in vivo microenvironment, with many different cell types present at a given time in the process.18,19 Healing wounds can take weeks or months to mend, and chronic wounds and severe burns do not heal at all or form hypertrophic scars that cause loss of function.20,21 Our in vitro studies rely on experiments performed on cells for up to 5 to 7 days; thus, prolonged experiments and animal models are required to address this. In addition to fibroblasts and mesenchymal stem cells, wound healing involves fibrocytes, keratinocytes, endothelial cells, and inflammatory immune cells that promote angiogenesis, reepithelialization, and tissue repair.18 In concert, these cells mediate the 4 essential stages of wound healing: hemostasis, inflammation, proliferation, and extracellular matrix remodeling/repair. The impact of these temporary wound dressings on different cell types, extracellular matrix remodeling, angiogenesis, and reepithelialization requires further study. Ultimately, in vivo studies are required to show effectiveness in wound healing; however, most in vivo models of wound healing have limitations as well. For example, while animal models are key in simulating human wound-healing conditions, many animals including mouse and rat show different mechanisms of healing (rodents primarily rely on wound contraction, whereas human healing relies heavily on reepithelialization).22-24 Therefore, these and other in vitro studies aimed at analyzing human cells are essential to show preliminary efficacy and mechanism of action in primary wound dressings.
CONCLUSION
Our results demonstrate that these acellular bilaminate primary dressings prevented scar-forming myofibroblast development and inflammatory mediator production in vitro. These data also reveal that temporary wound dressings have the potential to deliver or provide an anti-scarring effect to open wounds. In addition, gram-positive antimicrobial activity is detected with dressings coated with the antibiotic salinomycin. Further study is required to show the effect of these dressings in an in vivo setting.
1. Penn JW, Grobbelaar AO, Rolfe KJ. The role of the TGF-beta family in wound healing, burns and scarring: a review. Int J Burns Trauma. 2012;2:18-28. |
2. Huang JS, Wang YH, Ling TY, Chuang SS, Johnson FE, Huang SS. Synthetic TGF-beta antagonist accelerates wound healing and reduces scarring. FASEB J. 2002;16:1269-70. |
3. Dimmeler S, Zeiher AM. Netting insights into fibrosis. N Engl J Med. 2017;376:1475-7. |
4. Woeller CF, O'Loughlin CW, Roztocil E, Feldon SE, Phipps RP. Salinomycin and other polyether ionophores are a new class of antiscarring agent. J Biol Chem. 2015;290:3563-75. |
5. Tan H, Wasiak J, Paul E, Cleland H. Effective use of Biobrane as a temporary wound dressing prior to definitive split-skin graft in the treatment of severe burn: a retrospective analysis. Burns. 2015;41:969-76. |
6. Woodroof A, Phipps R, Woeller C, et al. Evolution of a biosynthetic temporary skin substitute: a preliminary study. Eplasty. 2015;15:e30. |
7. Klingberg F, Hinz B, White ES. The myofibroblast matrix: implications for tissue repair and fibrosis. J Pathol. 2013;229:298-309. |
8. Micallef L, Vedrenne N, Billet F, Coulomb B, Darby IA, Desmouliere A. The myofibroblast, multiple origins for major roles in normal and pathological tissue repair. Fibrogenesis Tissue Repair. 2012;5:S5. |
9. Woodroof EA, Phipps RP, Greenwood JE, Hickerson W, Herndon D. The search for an ideal temporary skin substitute: AWBAT Plus, a combination product wound dressing medical device. Eplasty. 2010;10:e60. |
10. Hansen TC, Woeller CF, Lacy SH, Koltz PF, Langstein HN, Phipps RP. Thy1 (CD90) expression is elevated in radiation-induced periprosthetic capsular contracture: implication for novel therapeutics. Plast Reconstr Surg. 2017;140:316-26. |
11. Lehmann GM, Woeller CF, Pollock SJ, et al. Novel anti-adipogenic activity produced by human fibroblasts. Am J Physiol Cell Physiol. 2010;299(3):C672-81. |
12. Gillaspy AF, Hickmon SG, Skinner RA, Thomas JR, Nelson CL, Smeltzer MS. Role of the accessory gene regulator (agr) in pathogenesis of staphylococcal osteomyelitis. Infect Immun. 1995;63:3373-80. |
13. Bonev B, Hooper J, Parisot J. Principles of assessing bacterial susceptibility to antibiotics using the agar diffusion method. J Antimicrob Chemother. 2008;61:1295-301. |
14. Jester JV, Petroll WM, Barry PA, Cavanagh HD. Expression of alpha-smooth muscle (alpha-SM) actin during corneal stromal wound healing. Invest Ophthalmol Vis Sci. 1995;36:809-19. |
15. Wang CY, Yang HB, Hsu HS, et al. Mesenchymal stem cell-conditioned medium facilitates angiogenesis and fracture healing in diabetic rats. J Tissue Eng Regen Med. 2012;6:559-69. |
16. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. Myofibroblasts, part I: paracrine cells important in health and disease. Am J Physiol. 1999;277:C1-9. |
17. Woeller CF, Roztocil E, Hammond CL, Feldon SE, Phipps RP. The aryl hydrocarbon receptor and its ligands inhibit myofibroblast formation and activation: implications for thyroid eye disease. Am J Pathol. 2016;186:3189-202. |
18. Greaves NS, Ashcroft KJ, Baguneid M, Bayat A. Current understanding of molecular and cellular mechanisms in fibroplasia and angiogenesis during acute wound healing. J Dermatol Sci. 2013;72:206-17. |
19. Demidova-Rice TN, Durham JT, Herman IM. Wound healing angiogenesis: innovations and challenges in acute and chronic wound healing. Adv Wound Care. 2012;1:17-22. |
20. Mustoe TA, Cooter RD, Gold MH, et al. International Advisory Panel on Scar Management. International clinical recommendations on scar management. Plast Reconstr Surg. 2002;110:560-71. |
21. Gilman TH. Silicone sheet for treatment and prevention of hypertrophic scar: a new proposal for the mechanism of efficacy. Wound Repair Regen. 2003;11:235-6. |
22. Seaton M, Hocking A, Gibran NS. Porcine models of cutaneous wound healing. ILAR J. 2015;56:127-38. |
23. Domergue S, Jorgensen C, Noel D. Advances in research in animal models of burn-related hypertrophic scarring. J Burn Care Res. 2015;36:e259-66. |
24. Abdullahi A, Amini-Nik S, Jeschke MG. Animal models in burn research. Cell Mol Life Sci. 2014;71:3241-55. |
| JOURNAL INFORMATION | ARTICLE INFORMATION |
| Journal ID: ePlasty | Volume: 18 |
| ISSN: 1937-5719 | E-location ID: e21 |
| Publisher: Open Science Company, LLC | Published: May 25, 2018 |
